Softbank’s Investment in WeWork: No Problem
The Japanese conglomerate's investment in a company whose CEO's business dealings are under fire won't derail its continuing success: Opinion.
The Simple Secret Behind Why Acquisitions Fail
Acquisitions are a zero-sum game: both buyer and seller need to feel they are getting a good deal. Unfortunately, buyers usually pay too much.
‘Threats’ to McKesson Don’t Hold Up
The drug distributor will remain a value stock despite some perceived threats, including the White House's aim to restructure pharmaceutical pricing.
Wall Street’s ‘Short Termism’ Misses the Point
Beating earnings estimates quarter after quarter doesn't have much to do with long-term shareholder value.
Investors Should Sell Apple Now: Contrarian Investor
Count the reasons why Apple's near-term financial future doesn't look too bright.
Caution: Stocks Are Historically Overvalued
Investor relations professionals should prepare for what's eventually inevitable: a reversion to the mean for stock prices.
Why Amazon’s Stock Isn’t as Great as You Think
For CFOs wanting to understand investor behavior, here's an argument that Jeff Bezos is human, after all, and Amazon can't defy basic economic principles.
Three Questions to Ask about Tesla
Will Elon Musk succeed with his strategy of wooing investors with promises for the future and one shiny new object after another?
So You Want To Know What the Market Will Do?
Forget it. No one knows what the stock market will do in the short term, and if someone says they do, they're a liar.
Is Exxon Riding Slowly into the Sunset?
If oil prices remain at current levels, at some point bond investors may no longer be willing to support the shrinking enterprise.
How Amazon Could Lose Its Health-Care Bid
The idea that the online retail-distribution giant could overtake large entrenched drug distributors like McKesson is far-fetched.